These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 15090815)

  • 1. Dose escalation or immediate full dose when switching from efavirenz to nevirapine-based highly active antiretroviral therapy in HIV-1-infected individuals?
    Winston A; Pozniak A; Smith N; Fletcher C; Mandalia S; Parmar D; Gibbons S; Back D; Gazzard B; Nelson M
    AIDS; 2004 Feb; 18(3):572-4. PubMed ID: 15090815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative biological and clinical outcomes after a switch from a virologically unsuccessful first protease inhibitor-containing antiretroviral combination to a 3-drug regimen containing efavirenz, nevirapine, or abacavir.
    Abgrall S; Yeni PG; Bouchaud O; Costagliola D;
    Clin Infect Dis; 2007 Jan; 44(1):120-7. PubMed ID: 17143827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study.
    van Leth F; Phanuphak P; Ruxrungtham K; Baraldi E; Miller S; Gazzard B; Cahn P; Lalloo UG; van der Westhuizen IP; Malan DR; Johnson MA; Santos BR; Mulcahy F; Wood R; Levi GC; Reboredo G; Squires K; Cassetti I; Petit D; Raffi F; Katlama C; Murphy RL; Horban A; Dam JP; Hassink E; van Leeuwen R; Robinson P; Wit FW; Lange JM;
    Lancet; 2004 Apr; 363(9417):1253-63. PubMed ID: 15094269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons.
    Veldkamp AI; Harris M; Montaner JS; Moyle G; Gazzard B; Youle M; Johnson M; Kwakkelstein MO; Carlier H; van Leeuwen R; Beijnen JH; Lange JM; Reiss P; Hoetelmans RM
    J Infect Dis; 2001 Jul; 184(1):37-42. PubMed ID: 11398107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efavirenz and nevirapine plasma levels in HIV-infected patients with hemophilia].
    Martorell M; López RM; Ribera E; Ruiz I; Tural C; Puig L; Monterde J
    Enferm Infecc Microbiol Clin; 2005; 23(6):349-52. PubMed ID: 15970167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study.
    Kappelhoff BS; van Leth F; MacGregor TR; Lange J; Beijnen JH; Huitema AD;
    Antivir Ther; 2005; 10(1):145-55. PubMed ID: 15751772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study.
    Manosuthi W; Sungkanuparph S; Tantanathip P; Lueangniyomkul A; Mankatitham W; Prasithsirskul W; Burapatarawong S; Thongyen S; Likanonsakul S; Thawornwa U; Prommool V; Ruxrungtham K;
    Clin Infect Dis; 2009 Jun; 48(12):1752-9. PubMed ID: 19438397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effectiveness of continuing a virologically effective first-line boosted protease inhibitor combination or of switching to a three-drug regimen containing either efavirenz, nevirapine or abacavir.
    Bommenel T; Launay O; Meynard JL; Gilquin J; Katlama C; Lascaux AS; Mahamat A; Martinez V; Pradier C; Rouveix E; Simon A; Costagliola D; Abgrall S;
    J Antimicrob Chemother; 2011 Aug; 66(8):1869-77. PubMed ID: 21636583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in Southern African adults.
    Nachega JB; Hislop M; Dowdy DW; Gallant JE; Chaisson RE; Regensberg L; Maartens G
    AIDS; 2008 Oct; 22(16):2117-25. PubMed ID: 18832875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of the treatment switch from efavirenz to nevirapine.
    Parienti JJ; Peytavin G; Reliquet V; Verdon R; Coquerel A
    Clin Infect Dis; 2010 Jun; 50(11):1547-8. PubMed ID: 20433360
    [No Abstract]   [Full Text] [Related]  

  • 11. Efavirenz replacement by immediate full-dose nevirapine is safe in HIV-1-infected patients in Cambodia.
    Laureillard D; Prak N; Fernandez M; Ngeth C; Moeung S; Riel V; Chhneang V; Song S; Quillet C; Piketty C
    HIV Med; 2008 Aug; 9(7):514-8. PubMed ID: 18554312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of nevirapine- and efavirenz-containing antiretroviral regimens in antiretroviral-naïve patients: a cohort study.
    Keiser P; Nassar N; White C; Koen G; Moreno S
    HIV Clin Trials; 2002; 3(4):296-303. PubMed ID: 12187503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does prior short-course nevirapine reduce the effectiveness of subsequent combination treatment with efavirenz?
    Fowler MG; Moorman A; Tong TC; Holmberg S; Greenberg AE
    J Acquir Immune Defic Syndr; 2003 Nov; 34(3):348-50. PubMed ID: 14600585
    [No Abstract]   [Full Text] [Related]  

  • 14. Once-daily highly active antiretroviral therapy for HIV-infected children: safety and efficacy of an efavirenz-containing regimen.
    Scherpbier HJ; Bekker V; Pajkrt D; Jurriaans S; Lange JM; Kuijpers TW
    Pediatrics; 2007 Mar; 119(3):e705-15. PubMed ID: 17308244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nevirapine plus efavirenz plus didanosine: a simple, safe, and effective once-daily regimen for patients with HIV infection.
    Jordan WC; Jefferson R; Yemofio F; Tolbert L; Conlon V; Carroll H; Green DC; Green A; Green R
    J Natl Med Assoc; 2003 Dec; 95(12):1152-7. PubMed ID: 14717471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial.
    Bonnet M; Bhatt N; Baudin E; Silva C; Michon C; Taburet AM; Ciaffi L; Sobry A; Bastos R; Nunes E; Rouzioux C; Jani I; Calmy A;
    Lancet Infect Dis; 2013 Apr; 13(4):303-12. PubMed ID: 23433590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study.
    Matthews GV; Sabin CA; Mandalia S; Lampe F; Phillips AN; Nelson MR; Bower M; Johnson MA; Gazzard BG
    AIDS; 2002 Jan; 16(1):53-61. PubMed ID: 11741163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adherence, virological and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapies.
    Braithwaite RS; Kozal MJ; Chang CC; Roberts MS; Fultz SL; Goetz MB; Gibert C; Rodriguez-Barradas M; Mole L; Justice AC
    AIDS; 2007 Jul; 21(12):1579-89. PubMed ID: 17630553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Higher efficacy of nevirapine than efavirenz to achieve HIV-1 plasma viral load below 1 copy/ml.
    Haïm-Boukobza S; Morand-Joubert L; Flandre P; Valin N; Fourati S; Sayon S; Lavignon M; Simon A; Girard PM; Katlama C; Calvez V; Marcelin AG
    AIDS; 2011 Jan; 25(3):341-4. PubMed ID: 21157295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Limits of deep salvage antiretroviral therapy with nelfinavir plus either efavirenz or nevirapine, in highly pre-treated patients with HIV disease.
    Manfredi R; Chiodo F
    Int J Antimicrob Agents; 2001 Jun; 17(6):511-6. PubMed ID: 11397623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.